Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.
Metabolism-mediated drug adverse effects (e.g., drug-drug interaction, bioactivation, etc.) strongly limit the utilization of clinical drugs. The present study aims to predict the metabolic capability of cytochrome P450 (CYP) 3A4 toward pazopanib which is an excellent drug exhibiting therapeutic role toward various cancers especially for ovarian cancer. Pazopanib can be well docked into the activity cavity of CYP3A4, and the interaction structure in pazopanib was methyl group located besides nitrogen in the five-membered ring. The distance between the hydrogen atom in methyl group and active center is 3.64 Å. The interaction amino acid is Glu374. Furthermore, both pazopanib and ketoconazole were docked into the activity cavity of CYP3A4 to compare their binding potential. The distance between ketoconazole and activity center (2.10 Å) is closer than the distance between pazopanib and activity center of CYP3A4, indicating the easy influence of CYP3A4 inhibitor toward the metabolism of pazopanib. All these data were helpful for the clinical application of pazopanib, and R&D of other tinib drug candidates as new anti-tumor drugs.
Qilu Hospital of Shandong University, Jinan, Shandong, China.|Linyi People's Hospital, Linyi, Shandong, China.
Xing-Jie
XJ
Liu
Qilu Hospital of Shandong University, Jinan, Shandong, China.|Linyi People's Hospital, Linyi, Shandong, China.
Hua
H
Lu
Linyi People's Hospital, Linyi, Shandong, China.
Ju-Xiang
JX
Sun
Linyi People's Hospital, Linyi, Shandong, China.
Su-Rong
SR
Wang
Linyi People's Hospital, Linyi, Shandong, China.
Yan-Shuai
YS
Mo
Qilu Hospital of Shandong University, Jinan, Shandong, China. xingshengyang@sdu.edu.cn.
Xing-Sheng
XS
Yang
Qilu Hospital of Shandong University, Jinan, Shandong, China.
Ben-Kang
BK
Shi
D000596:Amino Acids / Q000378:metabolism; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000494:pharmacology; D004347:Drug Interactions / Q000502:physiology; D005260:Female; D006801:Humans; D007191:Indazoles; D007654:Ketoconazole / Q000494:pharmacology; D062105:Molecular Docking Simulation / Q000379:methods; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010084:Oxidation-Reduction; D011743:Pyrimidines / Q000378:metabolism* / Q000494:pharmacology; D013449:Sulfonamides / Q000378:metabolism* / Q000494:pharmacology
D000596:Amino Acids; D000970:Antineoplastic Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D007654:Ketoconazole
Cytochrome P450 (CYP) 3A4; Drug–drug interaction; Pazopanib